IDH1, Histone Methylation, and So Forth

Virginie Penard-Lacronique; Olivier A Bernard

doi:10.1016/j.ccell.2016.07.008

IDH1, Histone Methylation, and So Forth

Cancer Cell. 2016 Aug 8;30(2):192-194. doi: 10.1016/j.ccell.2016.07.008.

Authors

Virginie Penard-Lacronique¹, Olivier A Bernard²

Affiliations

¹ INSERM U1170, 94805 Villejuif, France; Equipe Labellisée Ligue Nationale Contre le Cancer, Paris, France; Université Paris Sud, Université Paris-Saclay, 94720 Le Kremlin-Bicêtre, France; Gustave Roussy, Université Paris-Saclay, 94805 Villejuif, France. Electronic address: [email protected].
² INSERM U1170, 94805 Villejuif, France; Equipe Labellisée Ligue Nationale Contre le Cancer, Paris, France; Université Paris Sud, Université Paris-Saclay, 94720 Le Kremlin-Bicêtre, France; Gustave Roussy, Université Paris-Saclay, 94805 Villejuif, France. Electronic address: [email protected].

PMID: 27505668
DOI: 10.1016/j.ccell.2016.07.008

Abstract

IDH mutants cause aberrant DNA and histone methylation and contribute to hematological and neuronal malignancies. In this issue of Cancer Cell, Inoue et al. describe a potential specific effect of IDH1 mutations that reduces Atm expression via inhibition of H3K9 demethylases, which may represent a first step toward cellular transformation.

Publication types

Comment

MeSH terms

DNA Methylation
Histones / genetics*
Humans
Isocitrate Dehydrogenase / genetics*
Methylation
Mutation
Neoplasms / genetics

Substances

Histones
Isocitrate Dehydrogenase